|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Excessive IL-6 production and dysregulated IL-6 receptor signaling lead to multiple inflammatory and autoimmune diseases, such as asthma, even cancer.
|
31810605 |
2020 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-6 is a pro-inflammatory cytokine upregulated in some autoimmune diseases.
|
31809899 |
2020 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Objectives:</b> Oncostatin M (OSM), a pleiotropic cytokine and a member of the gp130/IL-6 cytokine family, has been implicated in the pathogenesis of autoimmune diseases.
|
31555281 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Otub1-deficient B cells display aberrantly activated phenotypes and overproduce the cytokine IL-6, contributing to autoimmunity induction.
|
31086255 |
2019 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Taken together, we show that NF-κB activated by inflammatory cytokines, such as IL-6 and TNF-α, ameliorates Foxp3 levels via regulating miR-34a expression, which provides a new mechanistic and therapeutic insight into the ongoing of autoimmune diseases.
|
31130368 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we review the IL-6 family of cytokines in autoimmune diseases, with a particular focus on the prototypical member IL-6, from the viewpoints of their structure, signaling, and biological features and discuss possible mechanisms of their functional pleiotropy.
|
30995501 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Th17 cytokines (IL-17A and IL-6) rose rapidly but declined as autoimmunity matured when Th1 cytokines (IL-12 and TNF) predominated.
|
31443998 |
2019 |
|
Autoimmune Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Aire can also be expressed in dendritic cells (DCs), and DCs can mediate T follicular helper (T<sub>FH</sub>) cell differentiation and self-reactive B cell activation through inducible costimulator molecule ligand (ICOSL) and interleukin 6 (IL-6), which can cause autoimmune diseases.
|
31023489 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, these data highlight that Cxxc1 as a key regulator governs the balance between T<sub>H</sub>17 and T<sub>reg</sub> cells by controlling the expression of IL-6Rα, which affects IL-6/STAT3 signaling and has an impact on T<sub>H</sub>17-related autoimmune diseases.
|
31633019 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
AT-rich interactive domain-containing protein 5a (Arid5a) is an RNA-binding protein (RBP) required for autoimmunity via stabilization of interleukin-6 (Il6) and signal transducer and activator of transcription 3 (STAT3) mRNAs.
|
29244194 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-6 has an important role in the pathogenesis of autoimmunity and chronic inflammation.
|
30178083 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Blockade of IL-6 family cytokines has been shown to be beneficial in autoimmune diseases, but bacterial infections and metabolic side effects have been observed.
|
28620096 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
|
29776017 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
However, few data on classic and trans-signaling IL-6 in autoimmune thyroid diseases and HIV<sup>+</sup> subjects developing autoimmune disorders are currently available.
|
29055566 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This study supports the potential of DC32 to down-regulate IL-6 for the treatment of RA and other related autoimmune diseases.
|
30336338 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we will review the role of IL-6 and IL-27 in inflammation, with a particular focus on inflammatory arthritis, and discuss their importance in the diagnosis, stratification and treatment of autoimmune disease.
|
29437229 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we discuss recent studies investigating how IL-6 regulates the CD4 T cell response in the context of autoimmune disease and highlight how blocking different aspects of the IL-6 pathway is advantageous in the treatment of disease.
|
30248523 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-6 is also an important regulator of adaptive immunity where it induces T cell differentiation and regulates autoimmunity.
|
29361380 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
So far, monoclonal antibodies against IL-6 or IL-6 receptor (IL-6R) and Janus kinases (JAK) inhibitors have been successfully developed for the treatment of autoimmune diseases such as rheumatoid arthritis.
|
29725131 |
2018 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Specific phase of this chronic and deteriorating disorder must be considered, which can involve IL-6 in acute or possible chronic inflammation and/or autoimmunity.
|
29163240 |
2017 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The AT-rich interactive domain-containing protein 5a (Arid5a) plays a critical role in autoimmunity by regulating the half-life of Interleukin-6 (IL-6) mRNA.
|
28168301 |
2017 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
These results suggest that a benzoxazole derivative, compound 4 effectively suppresses IL-6-STAT3 signaling and inflammatory cytokine production by T cells and provides a beneficial effect for treating chronic inflammatory and autoimmune disease.
|
28442260 |
2017 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
|
27547870 |
2017 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, NZ-IL6scFv may be an attractive tool for the research and development of new IL-6 targeting agents for various inflammatory and autoimmune diseases as well as for cancer.
|
27722916 |
2017 |
|
Autoimmune Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, more recent evidence from various autoimmune diseases (e.g., inflammatory bowel disease, rheumatoid arthritis) has shown that the IL-6 activity is more complex with important effects also on tissue homeostasis, regeneration, and metabolism.
|
28642760 |
2017 |